Mathé G - Search Results

1

An oriented phase II trial of THP-adriamycin in breast carcinoma.

Mathé G, Umezawa H, Oka S, Misset JL, Brienza S, de Vassal F, Musset M, Ribaud P, Tapiero H. Mathé G, et al. Biomed Pharmacother. 1986;40(10):376-9. Biomed Pharmacother. 1986. PMID: 3580506

2

Immunomodulating properties of bestatin in cancer patients. A phase II trial.

Mathé G, Umezawa H, Misset JL, Brienza S, Canon C, Musset M, Reizenstein P. Mathé G, et al. Biomed Pharmacother. 1986;40(10):379-82. Biomed Pharmacother. 1986. PMID: 3495299

3

A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP).

Mathé G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, Ecstein E, Despax R, Musset M, Misset JL. Mathé G, et al. Biomed Pharmacother. 1986;40(10):372-6. Biomed Pharmacother. 1986. PMID: 3580505

4

[Treatment of leukemias and lymphomas by interferons: II. Phase II of the trial treatment of chronic lymphoid leukemia by human interferon alpha+].

Misset JL, Mathé G, Gastiaburu J, Goutner A, Dorval T, Gouveia J, Schwarzenberg L, Machover D, Ribaud P, de Vassal F. Misset JL, et al. Among authors: mathe g. Biomed Pharmacother. 1982 Mar;36(2):112-6. Biomed Pharmacother. 1982. PMID: 7126777 French.

5

Phase I trial of Perrimustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme.

Kim-Triana B, Misset JL, Madelmont JC, Godenèche D, Musset M, Mathé G. Kim-Triana B, et al. Among authors: mathe g. Anticancer Drugs. 1992 Jun;3(3):225-31. doi: 10.1097/00001813-199206000-00004. Anticancer Drugs. 1992. PMID: 1525402

6

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.

Mathé G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, Misset JL, Brienza S, de Vassals F, Chenu E, et al. Mathé G, et al. Biomed Pharmacother. 1989;43(4):237-50. doi: 10.1016/0753-3322(89)90003-6. Biomed Pharmacother. 1989. PMID: 2675999

7

The differentiation-promoting potential of a cytostatic fluoro-pyranosyl adriamycin analog (FAD 104).

Blazsek I, Mathé G, Comisso M, Kitasato H, Umezawa K, Umezawa H. Blazsek I, et al. Among authors: mathe g. Biomed Pharmacother. 1989;43(4):267-70. doi: 10.1016/0753-3322(89)90007-3. Biomed Pharmacother. 1989. PMID: 2790148

8

A comparative trial of a MAOI, iproniazide, and a polycyclic agent, mianserine, for the search of the most rapidly and frequently active treatment of depressive syndromes in an oncology service.

Mathé G, Lopez MD, Fréchet M, de Vassal F, Brienza S, Gastiaburu J. Mathé G, et al. Biomed Pharmacother. 1987;41(1):13-26. Biomed Pharmacother. 1987. PMID: 3300808 Clinical Trial.

9

A phase II trial of immunorestoration with zinc gluconate in immunodepressed cancer patients.

Mathé G, Misset JL, Gil-Delgado M, Musset M, Reizenstein P, Canon C. Mathé G, et al. Biomed Pharmacother. 1986;40(10):383-5. Biomed Pharmacother. 1986. PMID: 3495300

10

Simultaneous detection in the bone marrow of mammary cancer metastatic cells and of their labelling index as respective markers of the residual minimum submacroscopic disease and its proliferative condition (preliminary results).

Ginsbourg M, Musset M, Misset JL, Genty O, Mathé G. Ginsbourg M, et al. Among authors: mathe g. Biomed Pharmacother. 1986;40(10):386-8. Biomed Pharmacother. 1986. PMID: 3555638

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,044 results

Search Page

Filters